Literature DB >> 24353015

Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.

Yuichi Yamada1, Kenichi Kohashi, Fumiyoshi Fushimi, Yusuke Takahashi, Nokitaka Setsu, Makoto Endo, Hidetaka Yamamoto, Shoji Tokunaga, Yukihide Iwamoto, Yoshinao Oda.   

Abstract

BACKGROUND: Solitary fibrous tumors (SFTs) are soft tissue tumors of intermediate malignancy that rarely metastasize. Although unresectable SFTs are reported to have a poor prognosis, to the authors' knowledge there is currently no effective therapy. Molecular target therapy is a promising approach for patients with unresectable tumors, but knowledge of the molecular biology of SFTs is currently insufficient to support such therapy. The current study investigated the activation of receptor tyrosine kinases (RTKs) and the Akt-mammalian target of rapamycin (Akt-mTOR) pathway in SFTs as therapeutic targets.
METHODS: The phosphorylation statuses of Akt-mTOR pathway proteins (p-Akt, p-mTOR, phosphorylated 4E-binding protein [p-4EBP1], and phosphorylated S6 ribosomal protein [p-S6RP]) and RTKs (phosphorylated platelet-derived growth factor receptor-α [p-PDGFRα], p-PDGFRβ, p-c-met, and phosphorylated insulin-like growth factor-1 receptor-β [p-IGF-1Rβ]) were assessed by immunohistochemistry in 66 samples of SFTs, and the data were compared with clinicopathological and histopathological findings. The expression of phosphorylated proteins was assessed by Western blot analysis in 6 frozen samples.
RESULTS: The immunohistochemical results were as follows: p-Akt, 56.0% (nuclear and cytoplasmic staining); p-mTOR, 69.6% (nuclear and cytoplasmic staining); p-4EBP1, 80.3% (nuclear and cytoplasmic staining); p-S6RP, 69.6% (cytoplasmic staining); p-PDGFRα, 39.0% (cytoplasmic staining); p-PDGFRβ, 52.0% (cytoplasmic staining); p-c-met, 37.8% (nuclear staining) and 19.6% (cytoplasmic staining); and p-IGF-1Rβ, 16.6% (nuclear staining). Phosphorylation of the Akt-mTOR pathway proteins was correlated with one another except for p-Akt with S6RP. p-PDGFRβ and p-IGF-1Rβ were correlated with p-Akt. Moreover, significant relationships were noted between disease-free survival or overall survival and the presence of hypoglycemia, necrosis, cystic and myxoid degeneration, and atypical findings.
CONCLUSIONS: The Akt/mTOR pathway was activated in approximately 50% of the cases of SFTs and was associated with RTKs, which were phosphorylated at different rates. Thus, the Akt-mTOR pathway may be involved in the tumorigenesis of SFTs.
© 2013 American Cancer Society.

Entities:  

Keywords:  Akt; hemangiopericytoma; mammalian target of rapamycin (mTOR); receptor tyrosine kinase; solitary fibrous tumor

Mesh:

Substances:

Year:  2013        PMID: 24353015     DOI: 10.1002/cncr.28506

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  [Metabolic disorders as paraneoplastic syndromes].

Authors:  S Krug; P Michl
Journal:  Internist (Berl)       Date:  2018-02       Impact factor: 0.743

2.  Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas.

Authors:  Takeaki Ishii; Kenichi Kohashi; Kunio Iura; Akira Maekawa; Hirofumi Bekki; Yuichi Yamada; Hidetaka Yamamoto; Kazuki Nabeshima; Hiroyuki Kawashima; Yukihide Iwamoto; Yoshinao Oda
Journal:  Tumour Biol       Date:  2015-10-30

3.  Clinicopathological review of solitary fibrous tumors: dedifferentiation is a major cause of patient death.

Authors:  Yuichi Yamada; Kenichi Kohashi; Izumi Kinoshita; Hidetaka Yamamoto; Takeshi Iwasaki; Masato Yoshimoto; Shin Ishihara; Yu Toda; Yoshihiro Itou; Yutaka Koga; Mikiko Hashisako; Yui Nozaki; Daisuke Kiyozawa; Daichi Kitahara; Takeshi Inoue; Munenori Mukai; Yumi Honda; Gouji Toyokawa; Kenji Tsuchihashi; Yoshifumi Matsushita; Fumiyoshi Fushimi; Kenichi Taguchi; Sadafumi Tamiya; Yumi Oshiro; Masutaka Furue; Yasuharu Nakashima; Satoshi Suzuki; Toru Iwaki; Yoshinao Oda
Journal:  Virchows Arch       Date:  2019-08-07       Impact factor: 4.064

4.  A novel mouse model of hemangiopericytoma due to loss of Tsc2.

Authors:  Heng Du; John R Dreier; Mahsa Zarei; Chin-Lee Wu; Roderick W Bronson; David J Kwiatkowski
Journal:  Hum Mol Genet       Date:  2018-12-15       Impact factor: 6.150

5.  Delayed pulmonary metastasis and recurrence of intracranial malignant solitary fibrous tumor/hemangiopericytoma: Case report and literature review.

Authors:  Qiheng Li; Chunmei Zhang; Zhengjin Li
Journal:  Oncol Lett       Date:  2022-06-14       Impact factor: 3.111

Review 6.  Update on Select Benign Mesenchymal and Meningothelial Sinonasal Tract Lesions.

Authors:  Lester D R Thompson; Julie C Fanburg-Smith
Journal:  Head Neck Pathol       Date:  2016-02-01

Review 7.  Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.

Authors:  J Musa; M F Orth; M Dallmayer; M Baldauf; C Pardo; B Rotblat; T Kirchner; G Leprivier; T G P Grünewald
Journal:  Oncogene       Date:  2016-02-01       Impact factor: 9.867

8.  Immunophenotype Heterogeneity in Nasal Glomangiopericytoma.

Authors:  Adriana Handra-Luca; Zakaria Y Abd Elmageed; Christina Magkou; Marick Lae
Journal:  Case Rep Otolaryngol       Date:  2015-08-17

9.  The pericyte antigen RGS5 in perivascular soft tissue tumors.

Authors:  Jia Shen; Swati Shrestha; Yu-Hsin Yen; Michelle A Scott; Chia Soo; Kang Ting; Bruno Peault; Sarah M Dry; Aaron W James
Journal:  Hum Pathol       Date:  2015-09-30       Impact factor: 3.466

10.  Pericyte Antigens in Perivascular Soft Tissue Tumors.

Authors:  Jia Shen; Swati Shrestha; Yu-Hsin Yen; Greg Asatrian; Marco Mravic; Chia Soo; Kang Ting; Sarah M Dry; Bruno Peault; Aaron W James
Journal:  Int J Surg Pathol       Date:  2015-06-17       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.